Cargando…

Serum albumin to globulin ratio prior to treatment as a potential non-invasive prognostic indicator for urological cancers

BACKGROUND: Numerous clinical studies have reported an association between the pretreatment albumin to globulin ratio (AGR) and survival outcomes of urological cancers. However, these conclusions remain controversial. Therefore, we performed a meta-analysis to explore the prognostic value of the AGR...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Zhongyou, Fu, Xueqin, Yuan, Xinzhu, Li, Jinze, Wang, Hao, Sun, Jing, Wu, Ji, Tang, Lingtong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643875/
https://www.ncbi.nlm.nih.gov/pubmed/36386921
http://dx.doi.org/10.3389/fnut.2022.1012181
_version_ 1784826616924340224
author Xia, Zhongyou
Fu, Xueqin
Yuan, Xinzhu
Li, Jinze
Wang, Hao
Sun, Jing
Wu, Ji
Tang, Lingtong
author_facet Xia, Zhongyou
Fu, Xueqin
Yuan, Xinzhu
Li, Jinze
Wang, Hao
Sun, Jing
Wu, Ji
Tang, Lingtong
author_sort Xia, Zhongyou
collection PubMed
description BACKGROUND: Numerous clinical studies have reported an association between the pretreatment albumin to globulin ratio (AGR) and survival outcomes of urological cancers. However, these conclusions remain controversial. Therefore, we performed a meta-analysis to explore the prognostic value of the AGR in urinary system tumors. METHODS: We retrieved eligible studies published up to June 2022 through a comprehensive search of multiple databases. Pooled hazard ratios (HRs) with 95% confidence intervals (CI) for overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), progression-free survival (PFS), and biochemical recurrence-free survival (BRFS) were used to evaluated the predictive effect of the AGR before treatment in urinary system tumors. Heterogeneity test, random-effects models, fixed-effects models and sensitivity tests were used for analyses. RESULTS: A total of 21 studies with 18,269 patients were enrolled in our meta-analysis. We found that patients with urinary system cancer with low AGR prior to treatment had poor OS [HR = 1.93, 95% CI (1.56–2.39), p < 0.001], CSS [HR = 2.22, 95% CI (1.67–2.96), p < 0.001], RFS [HR = 1.69, 95% CI (1.29–2.22), p < 0.001], and PFS [HR = 1.29, 95% CI (0.54–3.07), p < 0.001]. For prostate cancer (PCa), a low pretreatment AGR was associated with poor BRFS [HR = 1.46, 95% CI (1.28–1.67), p < 0.001]. Also, a subgroup analysis, stratified by ethnicity, cancer type, cutoff value, sample size and publication year, was conducted. The results showed that worse OS and CSS were significantly associated with these factors. CONCLUSION: Our meta-analysis revealed that the AGR before treatment could be used as a non-invasive predictive biomarker to evaluate the prognosis of urological cancer patients in clinical practice.
format Online
Article
Text
id pubmed-9643875
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96438752022-11-15 Serum albumin to globulin ratio prior to treatment as a potential non-invasive prognostic indicator for urological cancers Xia, Zhongyou Fu, Xueqin Yuan, Xinzhu Li, Jinze Wang, Hao Sun, Jing Wu, Ji Tang, Lingtong Front Nutr Nutrition BACKGROUND: Numerous clinical studies have reported an association between the pretreatment albumin to globulin ratio (AGR) and survival outcomes of urological cancers. However, these conclusions remain controversial. Therefore, we performed a meta-analysis to explore the prognostic value of the AGR in urinary system tumors. METHODS: We retrieved eligible studies published up to June 2022 through a comprehensive search of multiple databases. Pooled hazard ratios (HRs) with 95% confidence intervals (CI) for overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), progression-free survival (PFS), and biochemical recurrence-free survival (BRFS) were used to evaluated the predictive effect of the AGR before treatment in urinary system tumors. Heterogeneity test, random-effects models, fixed-effects models and sensitivity tests were used for analyses. RESULTS: A total of 21 studies with 18,269 patients were enrolled in our meta-analysis. We found that patients with urinary system cancer with low AGR prior to treatment had poor OS [HR = 1.93, 95% CI (1.56–2.39), p < 0.001], CSS [HR = 2.22, 95% CI (1.67–2.96), p < 0.001], RFS [HR = 1.69, 95% CI (1.29–2.22), p < 0.001], and PFS [HR = 1.29, 95% CI (0.54–3.07), p < 0.001]. For prostate cancer (PCa), a low pretreatment AGR was associated with poor BRFS [HR = 1.46, 95% CI (1.28–1.67), p < 0.001]. Also, a subgroup analysis, stratified by ethnicity, cancer type, cutoff value, sample size and publication year, was conducted. The results showed that worse OS and CSS were significantly associated with these factors. CONCLUSION: Our meta-analysis revealed that the AGR before treatment could be used as a non-invasive predictive biomarker to evaluate the prognosis of urological cancer patients in clinical practice. Frontiers Media S.A. 2022-10-26 /pmc/articles/PMC9643875/ /pubmed/36386921 http://dx.doi.org/10.3389/fnut.2022.1012181 Text en Copyright © 2022 Xia, Fu, Yuan, Li, Wang, Sun, Wu and Tang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Nutrition
Xia, Zhongyou
Fu, Xueqin
Yuan, Xinzhu
Li, Jinze
Wang, Hao
Sun, Jing
Wu, Ji
Tang, Lingtong
Serum albumin to globulin ratio prior to treatment as a potential non-invasive prognostic indicator for urological cancers
title Serum albumin to globulin ratio prior to treatment as a potential non-invasive prognostic indicator for urological cancers
title_full Serum albumin to globulin ratio prior to treatment as a potential non-invasive prognostic indicator for urological cancers
title_fullStr Serum albumin to globulin ratio prior to treatment as a potential non-invasive prognostic indicator for urological cancers
title_full_unstemmed Serum albumin to globulin ratio prior to treatment as a potential non-invasive prognostic indicator for urological cancers
title_short Serum albumin to globulin ratio prior to treatment as a potential non-invasive prognostic indicator for urological cancers
title_sort serum albumin to globulin ratio prior to treatment as a potential non-invasive prognostic indicator for urological cancers
topic Nutrition
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643875/
https://www.ncbi.nlm.nih.gov/pubmed/36386921
http://dx.doi.org/10.3389/fnut.2022.1012181
work_keys_str_mv AT xiazhongyou serumalbumintoglobulinratiopriortotreatmentasapotentialnoninvasiveprognosticindicatorforurologicalcancers
AT fuxueqin serumalbumintoglobulinratiopriortotreatmentasapotentialnoninvasiveprognosticindicatorforurologicalcancers
AT yuanxinzhu serumalbumintoglobulinratiopriortotreatmentasapotentialnoninvasiveprognosticindicatorforurologicalcancers
AT lijinze serumalbumintoglobulinratiopriortotreatmentasapotentialnoninvasiveprognosticindicatorforurologicalcancers
AT wanghao serumalbumintoglobulinratiopriortotreatmentasapotentialnoninvasiveprognosticindicatorforurologicalcancers
AT sunjing serumalbumintoglobulinratiopriortotreatmentasapotentialnoninvasiveprognosticindicatorforurologicalcancers
AT wuji serumalbumintoglobulinratiopriortotreatmentasapotentialnoninvasiveprognosticindicatorforurologicalcancers
AT tanglingtong serumalbumintoglobulinratiopriortotreatmentasapotentialnoninvasiveprognosticindicatorforurologicalcancers